4.72
price down icon4.45%   -0.22
after-market After Hours: 4.70 -0.02 -0.42%
loading
Atyr Pharma Inc stock is traded at $4.72, with a volume of 5.05M. It is down -4.45% in the last 24 hours and down -6.90% over the past month. aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$4.94
Open:
$4.9
24h Volume:
5.05M
Relative Volume:
1.55
Market Cap:
$420.10M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-15.03%
1M Performance:
-6.90%
6M Performance:
+22.28%
1Y Performance:
+138.38%
1-Day Range:
Value
$4.6499
$4.98
1-Week Range:
Value
$4.6499
$7.2904
52-Week Range:
Value
$1.67
$7.2904

Atyr Pharma Inc Stock (ATYR) Company Profile

Name
Name
Atyr Pharma Inc
Name
Phone
(858) 731-8389
Name
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Name
Employee
59
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
ATYR's Discussions on Twitter

Compare ATYR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ATYR
Atyr Pharma Inc
4.72 439.68M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
456.87 120.48B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.46 59.88B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
392.24 44.31B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
670.33 36.65B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
301.13 32.46B 3.81B -644.79M -669.77M -6.24

Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-18-25 Initiated Leerink Partners Outperform
Jan-06-25 Initiated Cantor Fitzgerald Overweight
Oct-04-24 Initiated Wells Fargo Overweight
Sep-05-24 Initiated Jefferies Buy
Jul-05-23 Downgrade Oppenheimer Outperform → Perform
Oct-12-21 Initiated RBC Capital Mkts Outperform
Sep-21-21 Initiated Piper Sandler Overweight
May-10-21 Initiated Laidlaw Buy
Aug-17-20 Upgrade H.C. Wainwright Neutral → Buy
Mar-04-20 Initiated ROTH Capital Buy
Mar-02-20 Initiated Oppenheimer Outperform
Feb-14-18 Downgrade JP Morgan Neutral → Underweight
Sep-07-17 Initiated Piper Jaffray Overweight
Dec-13-16 Downgrade JP Morgan Overweight → Neutral
Dec-16-15 Initiated Citigroup Neutral
Jun-01-15 Initiated Citigroup Buy
Jun-01-15 Initiated JP Morgan Overweight
View All

Atyr Pharma Inc Stock (ATYR) Latest News

pulisher
Jul 31, 2025

Martin Shkreli Is Shorting This ‘Strong Buy’ Penny Stock. How Should You Play Shares Here? - Yahoo Finance

Jul 31, 2025
pulisher
Jul 30, 2025

Price Channel Expanding on aTyr Pharma Inc.’s ChartReal Time Stock Movement Analysis Indicates Breakout - metal.it

Jul 30, 2025
pulisher
Jul 29, 2025

Price Consolidation Hints at Upcoming Move in aTyr Pharma Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Wyckoff Accumulation Phase Possible in aTyr Pharma Inc.Entry Plan for Oversold Reversal Stocks Released - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

Will aTyr Pharma Inc. Recover After Recent DeclineMarket Momentum Signal Generator Shows Trends - metal.it

Jul 29, 2025
pulisher
Jul 29, 2025

aTyr Pharma Inc put volume heavy and directionally bearish - TipRanks

Jul 29, 2025
pulisher
Jul 28, 2025

What makes aTyr Pharma Inc. stock price move sharplyTrend Analysis for Safer Trades Gains Popularity - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

aTyr Pharma Stock Faces Market Scrutiny Amid Financial Challenges - StocksToTrade

Jul 28, 2025
pulisher
Jul 28, 2025

aTyr Pharma Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Entry and Exit Point Tips From Traders - metal.it

Jul 28, 2025
pulisher
Jul 28, 2025

Is it the right time to buy aTyr Pharma Inc. stockAchieve breakthrough gains with smart trades - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are the technical indicators suggesting about aTyr Pharma Inc.Free Consultation - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does aTyr Pharma Inc. generate profit in a changing economyFree Stock Recommendation For Fast Growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What are aTyr Pharma Inc. company’s key revenue driversGet daily updates on the hottest stocks - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

What is aTyr Pharma Inc. company’s growth strategyBuild a portfolio with strong long-term growth - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

How volatile is aTyr Pharma Inc. stock compared to the marketUnstoppable trading performance - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 25, 2025

Is aTyr Pharma Inc. a good long term investmentUnprecedented market success - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

Does aTyr Pharma Inc. stock pay reliable dividendsHigh-performance investment picks - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

RNA Therapeutics and Vaccines Market Industry Trends & Forecasts to 2035, with Profiles of Alphavax, Arcturus Therapeutics, aTyr Pharma, Gritstone Bio, HDT Bio, MiNA Therapeutics, & VLP TherapeuticsResearchAndMarkets.com - FinancialContent

Jul 25, 2025
pulisher
Jul 23, 2025

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Benzinga

Jul 23, 2025
pulisher
Jul 23, 2025

aTyr Pharma Soars 11.26% on Phase 3 Study Completion - AInvest

Jul 23, 2025
pulisher
Jul 23, 2025

aTyr Pharma stock holds Buy rating as Phase 3 trial completes - Investing.com Canada

Jul 23, 2025
pulisher
Jul 23, 2025

High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout - TipRanks

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about aTyr Pharma Inc. stockMarket-leading capital gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

aTyr Pharma Announces Last Patient Visit in Phase 3 - GlobeNewswire

Jul 22, 2025
pulisher
Jul 22, 2025

What drives aTyr Pharma Inc. stock priceMarket-beating returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

aTyr Pharma Inc. Stock Analysis and ForecastFree Risk Assessment Services - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study - TipRanks

Jul 22, 2025
pulisher
Jul 22, 2025

First-Ever Global Phase 3 Trial for Sarcoidosis Treatment Reaches Major Milestone with 268 Patients - Stock Titan

Jul 22, 2025
pulisher
Jul 19, 2025

aTyr Pharma Reaches US$515m Market Cap Benefiting Insider Stock Buying - simplywall.st

Jul 19, 2025

Atyr Pharma Inc Stock (ATYR) Financials Data

There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$74.89
price down icon 3.43%
$36.80
price down icon 0.86%
$107.28
price up icon 2.00%
$26.37
price down icon 1.09%
$107.50
price down icon 2.32%
biotechnology ONC
$301.13
price up icon 0.40%
Cap:     |  Volume (24h):